<DOC>
	<DOC>NCT01998893</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin`s lymphoma. Patients will receive once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a second time in case of relapse (defined as progression after complete or partial response). The anticipated time on study treatment is &lt;3 months.</brief_summary>
	<brief_title>A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patients &gt;= 18 years of age; centrocytic centroblastic nonHodgkin`s lymphoma stage IIIIV; relapse after chemotherapy (with or without interferon maintenance therapy). primary refractory lymphomas; more than 3 relapses of centroblastic centrocytic nonHodgkin`s lymphoma; clinically significant cardiac disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>